Pfizer (PFE) Upgraded at Vetr
Vetr upgraded shares of Pfizer (NYSE:PFE) from a hold rating to a buy rating in a research note released on Monday morning. The brokerage currently has $37.98 price objective on the biopharmaceutical company’s stock.
Several other equities analysts have also commented on the stock. BMO Capital Markets set a $37.00 price objective on shares of Pfizer and gave the stock a buy rating in a report on Tuesday, October 10th. ValuEngine upgraded shares of Pfizer from a hold rating to a buy rating in a report on Friday, October 6th. Zacks Investment Research lowered shares of Pfizer from a buy rating to a hold rating in a report on Wednesday, October 11th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the stock a buy rating in a report on Wednesday, October 11th. Finally, Morgan Stanley upgraded shares of Pfizer from an equal weight rating to an overweight rating and upped their price objective for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $38.83.
Pfizer (PFE) traded down $0.02 during trading on Monday, hitting $36.54. 19,203,657 shares of the stock traded hands, compared to its average volume of 15,820,000. Pfizer has a twelve month low of $30.90 and a twelve month high of $37.35. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The stock has a market cap of $217,800.00, a PE ratio of 22.42, a price-to-earnings-growth ratio of 2.46 and a beta of 1.01.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter in the prior year, the company posted $0.61 EPS. The business’s revenue for the quarter was up .9% on a year-over-year basis. research analysts forecast that Pfizer will post 2.59 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. The ex-dividend date is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 dividend on an annualized basis and a yield of 3.72%. Pfizer’s dividend payout ratio is 78.53%.
Pfizer announced that its board has initiated a share buyback program on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its shares are undervalued.
In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now owns 103,458 shares in the company, valued at $3,827,946. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,450 shares of company stock worth $1,065,220. 0.06% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in PFE. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer in the 2nd quarter valued at $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in shares of Pfizer in the 2nd quarter valued at $103,000. D. Scott Neal Inc. raised its holdings in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares in the last quarter. Herndon Capital Management LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at $120,000. Finally, Americafirst Capital Management LLC acquired a new stake in shares of Pfizer in the 3rd quarter valued at $127,000. Institutional investors own 69.74% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Pfizer (PFE) Upgraded at Vetr” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/pfizer-pfe-upgraded-at-vetr/1804952.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with Analyst Ratings Network's FREE daily email newsletter.